TFX — Teleflex Incorporated stock price, charts and financials

QT64Teleflex Incorporated

Teleflex Incorporated (NYSE: TFX) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
135.70
+0.72+0.53%
TFXQT64Teleflex Incorporated·NYSE
135.70+0.53%
News
Up 0.5% — Why Teleflex (TFX) International Revenue Trends Deserve Your Attention (zacks.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-22.80Insider Own0.89%Shs Outstand44.27MPerf Week-1.27%
Market Cap5.98BForward P/E12.76EPS next Y10.58Insider Trans0.00%Shs Float43.91MPerf Month0.70%
Enterprise Value8.55BPEG-EPS next Q-Inst Own-Short Float6.34%Perf Quarter2.51%
Income-1.05BP/S2.30EPS this Y129.25%Inst Trans-Short Ratio3.92Perf Half Y27.47%
Sales2.60BP/B2.02EPS next Y58.69%ROA-15.17%Short Interest2.78MPerf YTD10.60%
Book/sh-P/C14.61EPS next 5Y19.70%ROE-31.83%52W High145.77 -6.91%Perf Year20.44%
Cash/sh-P/FCF15.30EPS past 3/5Y-ROIC1.30%52W Low100.71 34.74%Perf 3Y-45.71%
Dividend Est.1.36 (1.00%)EV/EBITDA-Sales past 3/5Y-10.62% -4.71%Gross Margin53.77%Volatility5.00% 3.50%Perf 5Y-66.04%
Dividend TTM1.36 (1.00%)EV/Sales3.29EPS Y/Y TTM-1640.54%Oper. Margin3.35%ATR (14)5.25Perf 10Y-25.25%
Dividend Ex-DateAug 14, 2026Quick Ratio2.12Sales Y/Y TTM-7.75%Profit Margin-39.58%RSI (14)51.31Recom2.48
Dividend Gr. 3/5Y0.00% 0.00%Current Ratio2.60EPS Q/Q-52.23%SMA200.18%Beta0.79Target Price152.57
Payout-5.82%Debt/Eq0.99Sales Q/Q-21.83%SMA502.54%Rel Volume1.32Prev Close134.98
Employees15,500LT Debt/Eq0.84EarningsNov 05SMA20011.14%Avg Volume565.35KPrice135.70
IPO DateMar 17, 1980Option/ShortYes / YesEPS/Sales Surpr.14.53% 2.12%Net Debt/EBITDA-10.81Volume748,077Change0.53%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-31-26ReiteratedNeedhamBuy$147$159
Jul-28-26InitiatedUBSNeutral$145
Jul-08-26InitiatedBMO CapitalOutperform$159
Jun-08-26UpgradePiper SandlerNeutralOverweight$245$160
May-08-26ReiteratedRaymond JamesOutperform$128$150
May-08-26ReiteratedMizuho SecuritiesNeutral$135$140
May-08-26UpgradeRBC CapitalSector PerformOutperform$135$155
Mar-27-26UpgradeRaymond JamesMarket PerformOutperform$355$128
Feb-26-26ReiteratedNeedhamBuy$138$147
Jan-29-26ReiteratedWells FargoEqual Weight$139$116
Latest News
Today
Aug-09-26
Aug-09-2606:04AM
Aug-06-26
Aug-04-26
Aug-03-26
Jul-31-26
Jul-29-26
Jul-27-26
Jul-23-26
Company

Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,6001,9933,047
Cost of Goods Sold Incl. D&A1,2038721,345
Gross Profit1,3981,1211,703
Selling, General and Administrative Excl. Other944720995
Research and Development195145162
Other Operating Expense1710395
Operating Income86256151
Interest Expense12010084
Unusual Expense
Non-Operating Income (Expense)-377-1318
Net Income Before Taxes-4102575
Income Taxes-35-345
Consolidated Net Income-1,029-90670
Net Income From Continuing Operations-3765970
Net Income-1,029-90670
EPS (Recurring)-23.28-20.301.49
EPS (Basic, Before Extraordinaries)-23.28-20.301.49
EPS (Diluted)-23.29-20.251.48
EBITDA-238303434
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio120.26
Price To Sales Ratio2.302.762.75
Gross Margin53.7756.2555.89
Operating Margin3.3112.844.96
Net Margin-39.58-45.462.30
Shares Outstanding444547
Market Capitalization5,9715,4928,365
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$146.09$133.16$120.23$107.30$94.37 Close Price0.00K158.40K316.80K475.19K633.59KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
HAGGERTY GRETCHEN RDirectorAug 06 '25Buy114.7550057,3756,305Aug 07
Ryu JaewonDirectorAug 05 '25Buy115.001,500172,5003,727Aug 07
Krakauer Andrew ADirectorAug 05 '25Buy115.251,000115,2507,192Aug 07
Kelly LiamChairman, President & CEOAug 05 '25Buy115.071,500172,60545,267Aug 07
RANDLE STUART ADirectorAug 05 '25Buy115.861,000115,8607,547Aug 07
Duncan Candace HDirectorMay 05 '25Option Exercise123.044,833594,6529,561May 07
Logue Daniel V.CVP, General Counsel & SectyFeb 20 '25Option Exercise121.001,620196,02014,328Feb 21
Klasko Stephen K. M.D.DirectorFeb 20 '25Option Exercise121.002,674323,5549,827Feb 21
Kelly LiamChairman, President & CEOFeb 19 '25Option Exercise121.4136,4644,427,19963,556Feb 21
RANDLE STUART ADirectorAug 16 '24Option Exercise121.002,674323,5548,170Aug 16
RANDLE STUART ADirectorAug 16 '24Sale238.932,674638,8995,496Aug 16
Hicks Cameron PCorp. VP & Chief HR OfficerMar 05 '24Option Exercise135.147,4011,000,19717,451Mar 05
Hicks Cameron PCorp. VP & Chief HR OfficerMar 05 '24Sale225.007,4011,665,22510,050Mar 05
Logue Daniel V.CVP, General Counsel & SectyFeb 26 '24Option Exercise101.121,525154,20812,278Feb 28
Kelly LiamChairman, President & CEODec 27 '23Option Exercise101.8726,2562,674,57144,726Dec 29
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.